AI Article Synopsis

  • The study looked at brain structure differences in schizophrenia versus affective psychoses and how lifetime use of antipsychotics or benzodiazepines affects brain morphology.
  • Researchers analyzed brain MRI scans of people from the Northern Finland Birth Cohort 1966, finding no volume differences between the two groups.
  • For schizophrenia, higher antipsychotic doses correlated with reduced nucleus accumbens volume, while in affective psychoses, higher benzodiazepine doses were linked to increased gray matter and hippocampal volume, suggesting the need for independent examination of benzodiazepine effects.

Article Abstract

The aim of this paper was to investigate differences in brain structure volumes between schizophrenia and affective psychoses, and whether cumulative lifetime antipsychotic or benzodiazepine doses relate to brain morphology in these groups. We conducted two systematic reviews on the topic and investigated 44 schizophrenia cases and 19 with affective psychoses from the Northern Finland Birth Cohort 1966. The association between lifetime antipsychotic and benzodiazepine dose and brain MRI scans at the age of 43 was investigated using linear regression. Intracranial volume, sex, illness severity, and antipsychotic/benzodiazepine doses were used as covariates. There were no differences between the groups in brain structure volumes. In schizophrenia, after adjusting for benzodiazepine dose and symptoms, a negative association between lifetime antipsychotic dose and the nucleus accumbens volume remained. In affective psychoses, higher lifetime benzodiazepine dose associated with larger volumes of total gray matter and hippocampal volume after controlling for antipsychotic use and symptoms. It seems that in addition to antipsychotics, the severity of symptoms and benzodiazepine dose are also associated with brain structure volumes. These results suggest, that benzodiazepine effects should also be investigated also independently and not only as a confounder.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pscychresns.2018.08.015DOI Listing

Publication Analysis

Top Keywords

affective psychoses
16
benzodiazepine dose
16
antipsychotic benzodiazepine
12
brain structure
12
structure volumes
12
lifetime antipsychotic
12
brain morphology
8
schizophrenia affective
8
systematic reviews
8
birth cohort
8

Similar Publications

Background: Neuropsychiatric symptoms (NPS) constitute a major challenge for patients with Alzheimer’s disease (AD). We have recently demonstrated that in AD, overall NPS burden is significantly associated with patient function. However, few studies have examined the relationship between specific symptom clusters with neurological biomarkers.

View Article and Find Full Text PDF

Background: This study evaluated the prevalence of various mental disorders and their influence on mortality outcomes in individuals with cancer.

Methods: The authors' institutional database included patients with cancer diagnosed between 2011 and 2015 who had mental disorders and death information up to 2021. Mental disorders included nonaffective psychotic disorders, affective psychotic disorders, anxiety-related and stress-related disorders, alcohol or drug misuse, and mood disorders without psychotic symptoms.

View Article and Find Full Text PDF

Electroconvulsive Therapy-Induced Mania in Bipolar Disorder: A Case Report.

Cureus

December 2024

Psychiatry, Psychiatrisch Ziekenhuis Asster, Sint-Truiden, BEL.

Electroconvulsive therapy (ECT) is widely recognized as a safe and effective intervention for treating severe affective episodes in patients with bipolar disorder. However, it can sometimes precipitate unexpected manic phases in patients treated for a depressive episode, a phenomenon known as ECT-induced mania. While this occurrence is recognized, it remains poorly understood and minimally addressed in the literature.

View Article and Find Full Text PDF

Efficacy of Lurasidone in First-Episode Psychosis: Patient Phenotypes, Dosage, and Recommendations from an Expert Panel.

Neurol Ther

January 2025

Department of Psychiatry, Faculty of Medicine, Mental Health Unit, Virgen del Rocio University Hospital, Translational Psychiatry Group, IBiS-CSIC, CIBERSAM, University of Seville, Seville, Spain.

Introduction: For patients with psychosis, early, intensive therapeutic intervention is thought to improve long-term outcomes. Furthermore, patients with a first-episode psychosis (FEP) who experience a good early response to antipsychotic medication show a clinical and functional benefit over the longer term if they continue low-dose antipsychotic treatment. Lurasidone is an atypical antipsychotic agent which is approved in Europe for the treatment of schizophrenia in adults and adolescents (13-17 years).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!